Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC.

BMC Med Res Methodol

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.

Published: January 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881308	PMC
http://dx.doi.org/10.1186/s12874-023-01850-7	DOI Listing

Publication Analysis

correction individual

individual patient

patient data

data allow

allow elaborated

elaborated comparison

comparison trial

trial real-world

real-world outcomes

outcomes second-line

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!